Similar articles

• Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial.

  Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, Atkins RC, Nicholls K, Fraenkel M, Hutchison BG, Walker R, McNeil JJ. Zoungas S, et al. J Am Coll Cardiol. 2006 Mar 21;47(6):1108-16. doi: 10.1016/j.jacc.2005.10.064. Epub 2006 Feb 23. J Am Coll Cardiol. 2006. PMID: 16545638 Clinical Trial.
• "New" cardiovascular risk factors in patients with chronic kidney disease: role of folic acid treatment.

  Bayés B, Pastor MC, Bonal J, Romero R. Bayés B, et al. Kidney Int Suppl. 2005 Jan;(93):S39-43. doi: 10.1111/j.1523-1755.2005.09309.x. Kidney Int Suppl. 2005. PMID: 15613067 Review.
• Atherosclerosis and folic acid supplementation trial in chronic renal failure: baseline results.

  Zoungas S, Branley P, Kerr PG, Ristevski S, Muske C, Demos L, Atkins RC, Becker G, Fraenkel M, Hutchison BG, Walker R, McNeil JJ, McGrath BP. Zoungas S, et al. Nephrology (Carlton). 2004 Jun;9(3):130-41. doi: 10.1111/j.1440-1797.2004.00242.x. Nephrology (Carlton). 2004. PMID: 15189174 Clinical Trial.
• [Group B vitamins as new variables related to the cardiovascular risk].

  Granieri M, Bellisarii FI, De Caterina R. Granieri M, et al. Ital Heart J Suppl. 2005 Jan;6(1):1-16. Ital Heart J Suppl. 2005. PMID: 15776726 Review. Italian.
• Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.

  Heinz J, Kropf S, Luley C, Dierkes J. Heinz J, et al. Am J Kidney Dis. 2009 Sep;54(3):478-89. doi: 10.1053/j.ajkd.2009.01.266. Epub 2009 Apr 8. Am J Kidney Dis. 2009. PMID: 19359080